Blood biomarkers for Alzheimer's disease: Reliable change and impacts of renal and blood-brain barrier function.

ABSTRACT:

Introduction

Blood-based biomarkers for Alzheimer's disease (AD) have the potential to improve diagnostic accessibility, but their clinical interpretation requires understanding of variability and biological influences.

Methods

We repeatedly sampled blood from 57 adults referred for lumbar puncture as part of a cognitive evaluation at a memory clinic. We measured serum phosphorylated- tau-181 (s-p-tau181) and plasma amyloid beta (Aβ)42/40 ratio (p-Aβ42/Aβ40) and evaluated the impact of renal and blood-brain barrier (BBB) function.

Results

Test-retest analysis revealed large variability of s-p-tau181 and small for p-Aβ42/Aβ40. Markers of renal function and BBB integrity significantly influenced s-p-tau181 levels, whereas p-Aβ42/Aβ40 was not affected.

Discussion

SUBMITTER: Behrens A 

PROVIDER: S-EPMC12417335 | biostudies-literature | 2025 Jul-Sep

REPOSITORIES: biostudies-literature